过去 4 年来，造血细胞移植 (HCT) 的应用不断扩大，覆盖了年龄较大且合并症较多的人群。这些患者在 HCT 后面临心血管疾病的风险增加。风险因多种因素而异，包括移植类型（自体或同种异体）。 HCT 中使用的许多疗法都可能具有心脏毒性。 HCT后的心血管并发症包括房性心律失常、心力衰竭、心肌梗死和心包积液。在 HCT 之前，患者应接受全面的心血管评估，并根据个人心血管风险水平进行持续监测。在这篇综述中，我们概述了 HCT 后的心脏毒性，并概述了我们的风险评估和持续护理方法。© 2024 作者。

The use of hematopoietic cell transplantation (HCT) has expanded in the last 4 decades to include an older and more comorbid population. These patients face an increased risk of cardiovascular disease after HCT. The risk varies depending on several factors, including the type of transplant (autologous or allogeneic). Many therapies used in HCT have the potential to be cardiotoxic. Cardiovascular complications after HCT include atrial arrhythmias, heart failure, myocardial infarction, and pericardial effusions. Before HCT, patients should undergo a comprehensive cardiovascular assessment, with ongoing surveillance tailored to their individual level of cardiovascular risk. In this review, we provide an overview of cardiotoxicity after HCT and outline our approach to risk assessment and ongoing care.© 2024 The Authors.